Centessa Pharmaceuticals plc
centessa.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2026 10-Q, filed May 5, 2026. Its latest SEC filing is a SCHEDULE 13G/A from Aug 14, 2026.
10-Q for Q1 FY2026, filed May 5, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops small-molecule orexin-activating drug candidates for people with sleep-wake disorders and other neurological, neurodegenerative and neuropsychiatric conditions.
10-K for FY2025, filed Mar 31, 2026
How Did They Make Money?
Receives upfront license payments and may receive additional payments when a partner takes commercial licenses or reaches development, regulatory or sales milestones, plus royalties on licensed product sales. It has also received non-recurring out-licensing revenue.
10-K for FY2025, filed Mar 31, 2026On February 14, 2025, the Company entered into a license agreement (the “License Agreement”) with Genmab pursuant to which the Company…View ↗
Under the terms of the License Agreement, the Company received a non-refundable upfront payment of $15.0 million related to the license of…View ↗
While we received non-recurring revenue related to out-licensing in the past (including most recently the limited out-license of the…View ↗
$15M
-
10-K for FY2025, filed Apr 1, 2026
$15M ↗
Who Were Their Customers?
Genmab pays for access to Centessa’s LockBody technology and may take commercial licenses for selected targets.
10-K for FY2025, filed Mar 31, 2026
Did Revenues Turn Into Profits?
No. It lost $197.5M in FY2025.
10-K for FY2025, filed Apr 1, 2026
−$207.7MView ↗
10-K for FY2025, filed Apr 1, 2026
−$197.5MView ↗
10-K for FY2025, filed Apr 1, 2026
−$194.2MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2026, filed May 6, 2026
−$79.2MView ↗
- ▲ +203% (Loss)
- vs −$26.1M in Q1 FY2025
-
Jun 24, 2026
Lilly completed its acquisition of Centessa.
Centessa became a wholly owned Lilly subsidiary; shareholders became entitled to $38.00 per share in cash plus a contingent value right.
Sources
8-K, filed Jun 24, 2026
At the Effective Time, Purchaser acquired all of the issued and outstanding ordinary shares of Centessa, with a nominal value of £0.002 per…View ↗
From a broad pipeline to orexin
The earlier report described programs across hemophilia, cancer, orexin and other diseases. The latest report centers the business on orexin medicines, with cleminorexton its most advanced candidate and follow-up orexin candidates in development.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 31, 2026Our most advanced product candidate is SerpinPC, a subcutaneously administered novel inhibitor of activated protein C (“APC”) being…View ↗
Leveraging our proprietary LockBody® technology, we are also pioneering a novel approach to selectively drive potent effector function…View ↗
Our other programs consist of earlier-stage preclinical assets including our newest product candidate, ORX750, an orally administered…View ↗
We are a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. We are developing a…View ↗
Our most advanced product candidate, cleminorexton (formerly referred to as ORX750), is a novel, oral, highly potent and selective orexin…View ↗
Supported by differentiated pharmacology, strong orexin biology, compelling translational and clinical rationale, and insights from the…View ↗
Who Did They Compete With?
Competes with Takeda Pharmaceuticals and Alkermes
10-K for FY2025, filed Mar 31, 2026The biotechnology and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding of disease…View ↗
Loading...
